Data from the PACIFIC Trial in Stage 3 Non-Small Cell Lung CancerByTargeted OncologyNovember 16th 2020Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.
Evolving Approaches for HCC in the Molecular Medicine EraByTargeted OncologyNovember 5th 2020An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.
Case 2: Role of L-MIND Regimen as Second-Line Treatment in Transplant Ineligible DLBCL ByTargeted OncologyOctober 28th 2020
Case 2: Phase 2 L-MIND Clinical Trial for Relapsed/Refractory DLBCLByTargeted OncologyOctober 28th 2020
Case 2: Considerations for Choosing a Second-Line Therapy for DLBCLByTargeted OncologyOctober 28th 2020
Case 2: Therapeutic Options in Patients With Transplant-Ineligible, Treatment-Refractory DLBCLByTargeted OncologyOctober 28th 2020
Case 1: Therapeutic Options After CAR T-Cell in Relapsed/Refractory DLBCLByTargeted OncologyOctober 28th 2020
Case 1: Trials in CAR T-Cell for Patients With Relapsed/Refractory DLBCLByTargeted OncologyOctober 28th 2020
Case 1: Therapy for Relapsed DLBCL in Transplant-Eligible PatientsByTargeted OncologyOctober 28th 2020